Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.

This study showed that the benefit of treating patients with PMS was mostly confined to those with the more active disease. Drugs targeting specific pathological processes leading to disability progression remain necessary.